| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/27/2015 | US8940707 Maribavir isomers, compositions, methods of making and methods of using |
| 01/27/2015 | US8940705 Method of treating disease and selectively modulating transcriptional regulation by a glucocorticoid receptor by administering aclacinomycin and dexamethasone |
| 01/27/2015 | US8940701 Compounds for, and methods of, treating cancer and inhibiting invasion and metastases |
| 01/27/2015 | US8940695 Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| 01/27/2015 | US8940683 Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
| 01/27/2015 | US8940674 High alcohol content foaming compositions |
| 01/27/2015 | US8940497 Enzyme regulating ether lipid signaling pathways |
| 01/27/2015 | US8940479 Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity |
| 01/27/2015 | US8940339 Microemulsions and its use for preventing airway diseases |
| 01/27/2015 | US8940338 Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy |
| 01/27/2015 | US8940334 Pharmaceutical composition of an anthracycline |
| 01/27/2015 | US8940333 Amphiphilic block copolymers and nanoparticles comprising the same |
| 01/27/2015 | US8940332 High-molecular weight conjugate of podophyllotoxins |
| 01/27/2015 | US8940330 Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
| 01/27/2015 | US8940329 High ibuprofen content granules and their preparation and their use in pharmaceutical dosage forms |
| 01/27/2015 | US8940328 Pellet formulation for the treatment of the intestinal tract |
| 01/27/2015 | US8940327 Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation |
| 01/27/2015 | US8940326 Transdermal patch and method for delivery of vitamin B12 |
| 01/27/2015 | US8940325 Use of synthetic polysulphated oligosaccharides as cleaning agents for a wound |
| 01/27/2015 | US8940324 Octenidine composition |
| 01/27/2015 | US8940321 Compositions for treatment of ear disorders and methods of use thereof |
| 01/27/2015 | US8940320 Dental implant and production method for said implant |
| 01/27/2015 | US8940318 Hydrogel contact lens for sustained drug release and drug release method using hydrogel contact lens for sustained drug release |
| 01/27/2015 | US8940315 Benzodiazepine formulation in a polyorthoester carrier |
| 01/27/2015 | US8940313 Tyrosine-based prodrugs of antiviral agents |
| 01/27/2015 | US8940312 Composition containing polyunsaturated fatty acid |
| 01/27/2015 | US8940310 Methods of treatment using TLR7 and/or TLR9 inhibitors |
| 01/27/2015 | US8940306 Method for enhancing immune response with peptide |
| 01/27/2015 | US8940291 Compositions and methods for enhancing virus efficacy |
| 01/27/2015 | US8940281 Composition using cross-linked hyaluronic acid for topical cosmetic and therapeutic applications |
| 01/27/2015 | US8940271 Transmucosal administration of drug compositions for treating and preventing disorders in animals |
| 01/27/2015 | CA2820479C Patch and method for producing the same |
| 01/27/2015 | CA2797904C Paste-like bone cement |
| 01/27/2015 | CA2789140C Synthesis of magnolol and its analogue compounds |
| 01/27/2015 | CA2768882C Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| 01/27/2015 | CA2766104C Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof |
| 01/27/2015 | CA2760714C A device for coating a medical implant and a method for using same |
| 01/27/2015 | CA2747996C Compounds and methods for enhancing erythropoiesis |
| 01/27/2015 | CA2703645C Composition for reducing the level of glucose, malondialdehyde-modified ldl, homocysteine and/or c-reactive protein in blood |
| 01/27/2015 | CA2692166C Substituted (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides and use thereof in the field of blood coagulation |
| 01/27/2015 | CA2676786C Imidazoquinolines as dual lipid kinase and mtor inhibitors |
| 01/27/2015 | CA2673917C Cycloalkylamine substituted isoquinolone derivatives |
| 01/27/2015 | CA2671622C Treatment of cachexia |
| 01/27/2015 | CA2671517C Method of radio-sensitizing tumors using a radio-sensitizing agent |
| 01/27/2015 | CA2670976C Cyclic amine compound |
| 01/27/2015 | CA2668399C Thiazole and oxazole-substituted arylamides |
| 01/27/2015 | CA2664893C Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors |
| 01/27/2015 | CA2659875C Multifunctional bioactive compounds |
| 01/27/2015 | CA2657335C Use of ampk-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them |
| 01/27/2015 | CA2656451C Composition comprising a retinoid and benzoyl peroxide |
| 01/27/2015 | CA2652841C New benzothiazinone derivatives and their use as antibacterial agents |
| 01/27/2015 | CA2652834C Substituted arylimidazolones and -triazolones and the use thereof |
| 01/27/2015 | CA2651890C Controlled dose drug delivery system |
| 01/27/2015 | CA2651646C Antibacterial extracellular polysaccharide solvating system comprising a metal ion sequestering agent |
| 01/27/2015 | CA2650695C Methods for treating or preventing disorders using ecdysteroid compositions |
| 01/27/2015 | CA2649175C Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders |
| 01/27/2015 | CA2642205C Bicyclic imidazole or thiadiazole heterocycles useful as selective androgen receptor modulators |
| 01/27/2015 | CA2632561C Substituted propofol derivatives as analgesics |
| 01/27/2015 | CA2630203C 3,6-dihydro-2-oxo-6h-1,3,4-thiadiazine derivatives |
| 01/27/2015 | CA2600985C 1-subsituted-3,4-dihydro-pthalazin-4-ones as eg5 inhibitors |
| 01/27/2015 | CA2584279C Compositions and methods for stabilizing liposomal drug formulations |
| 01/27/2015 | CA2577468C Composition and method for pre-surgical skin disinfection |
| 01/27/2015 | CA2569428C Methods and devices for treating vulnerable plaque |
| 01/27/2015 | CA2562277C Methods of using sustained release aminopyridine compositions |
| 01/27/2015 | CA2538802C Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
| 01/27/2015 | CA2538135C 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses |
| 01/27/2015 | CA2515699C Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| 01/27/2015 | CA2481386C Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| 01/27/2015 | CA2480311C Oligomeric compounds for the modulation of hif-1alpha expression |
| 01/27/2015 | CA2470104C Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
| 01/23/2015 | CA2856886A1 New phosphate derivatives, their preparation process and the pharmaceutical compounds containing them |
| 01/23/2015 | CA2856505A1 New pyrrole derivatives, their preparation process and the pharmaceutical compounds containing them |
| 01/22/2015 | WO2015010107A1 Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia |
| 01/22/2015 | WO2015010106A1 Methods and compositions for prevention of allergic reaction |
| 01/22/2015 | WO2015010102A1 Methods and compositions for treatment of fibrosis |
| 01/22/2015 | WO2015010096A1 Method of enhancing potency of immune cells |
| 01/22/2015 | WO2015010092A1 Heat-stable dry powder pharmaceutical compositions and methods |
| 01/22/2015 | WO2015010084A1 Colorimetric phytic acid assay |
| 01/22/2015 | WO2015010078A2 Substituted 6,5-fused bicyclic heteroaryl compounds |
| 01/22/2015 | WO2015010065A1 Sulfonamides as modulators of sodium channels |
| 01/22/2015 | WO2015010054A2 Neuroactive steroids, compositions, and uses thereof |
| 01/22/2015 | WO2015010049A1 Substituted benzene compounds |
| 01/22/2015 | WO2015010032A1 Anti-cancer compounds |
| 01/22/2015 | WO2015010014A1 Treatment for obesity |
| 01/22/2015 | WO2015009956A1 Use of nitrated lipids for treatment of side effects of toxic medical therapies |
| 01/22/2015 | WO2015009930A2 Novel phosphodiesterase inhibitors and uses thereof |
| 01/22/2015 | WO2015009927A1 Dolutegravir salts |
| 01/22/2015 | WO2015009913A1 Methods and systems for incorporating nicotine into oral products |
| 01/22/2015 | WO2015009902A1 Compositions comprising exemestane and novel methods of use |
| 01/22/2015 | WO2015009897A1 Compositions and methods for preserving red blood cells and platelets |
| 01/22/2015 | WO2015009889A1 Deuterated intedanib derivatives and their use for the treatment of proliferative disorders |
| 01/22/2015 | WO2015009883A1 Activators of nad-dependent protein deacteylases and uses thereof |
| 01/22/2015 | WO2015009882A2 Cyano derivatives and their uses |
| 01/22/2015 | WO2015009881A1 Nrf2 inhibitors and compositions for treating mycobacterial infections |
| 01/22/2015 | WO2015009879A1 Compositions for modulating nrf2-are activity and their methods of use |
| 01/22/2015 | WO2015009851A1 Methods of treating cancer in subjects afflicted with metabolic dysfunction |
| 01/22/2015 | WO2015009841A2 Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof |
| 01/22/2015 | WO2015009831A2 Methods of treating urothelial carcinomas |
| 01/22/2015 | WO2015009812A2 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof |
| 01/22/2015 | WO2015009809A1 Mouth wash compositions for denture adhesive removal |